TAKHZYRO (lanadelumab) for injection

TAKHZYRO contains the active substance lanadelumab. TAKHZYRO is a prescriptio medicine used in adults, and adolescents aged 12 years and older to prevent
angioedema attacks, in patients with hereditary angioedema (HAE). Brand Name: TAKHZYRO 300 mg solution for injection

Home | lanadelumab for injection

TAKHZYRO (lanadelumab) for injection Price In India and Overseas
TAKHZYRO 300 mg solution for injection

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Indian Patient Enquiry under NPP.

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

TAKHZYRO 300 mg solution for injection

The US Food and Drug Administration approved the use of lanadelumab in August 2018, for people that are 12 years and older and have either type I or type II hereditary angioedema.

Takhzyro is given as an injection under the skin, preferably in the abdomen (belly), thighs or upper arms. The recommended starting dose of Takhzyro is 300 mg every 2 weeks. If the patient remains free of attacks with the two-weekly dose, the doctor can reduce the frequency to once every 4 weeks. The doctor may decide that patients or their caregivers can inject the medicine themselves after they have been properly trained. Takhzyro can only be obtained with a prescription and should be started under supervision of a doctor experienced in managing hereditary angioedema. For more information about using Takhzyro, see the package leaflet or contact your doctor or pharmacist.

Lanadelumab, sold under the brand name Takhzyro, is a human monoclonal antibody (class IgG1 kappa) that targets plasma kallikrein (pKal) in order to promote prevention of angioedema in people with hereditary angioedema.[8][9] Lanadelumab, was approved in the United States as the first monoclonal antibody indicated for prophylactic treatment to prevent hereditary angioedema attacks. Lanadelumab is the first treatment for hereditary angioedema prevention made by using cells within a lab, not human plasma.

Drug (Brand / Generic): TAKHZYRO / lanadelumab
Current Indications: Angioedemas, Hereditary
Marketed by:: Takeda Pharmaceuticals International AG Ireland Branch
Approval Date: 22/11/2018

Dosage forms and strengths of TAKHZYRO 300 mg solution for injection
TAKHZYRO 300 mg solution for injection
TAKHZYRO 300 mg solution for injection in pre-filled syringe

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.